Vnitr Lek 2016, 62(Suppl 3):77-81

TSH secreting adenomas

Jana Ježková*, Josef Marek
III. interní klinika 1. LF UK a VFN v Praze

Adenomas which secrete thyrotropic hormone (thyrotropinomas) are rare and constitute less than 3 % of pituitary adenomas. In laboratory studies there is a typical elevation of thyroid hormones with nonsupressible TSH. In differential diagnostics it is necessary to distinguish above all the syndrome of resistance to thyroid hormones. Clinical symptoms are usually mild and correspond to symptoms of hyperthyroidism. Goiter is a common finding. In 80 % of cases thyrotropinomas are diagnosed in a stage of invasively growing macroadenoma. The primary treatment is neurosurgical removal adenoma which results in cure in 40 % of patients. Other treatment options include radiation therapy and medical treatment (treatment with somatostatin analogues). With regard to the risk of adenoma recurrence, the long-term follow-up is similar to that of cases of other pituitary adenomas necessary.

Keywords: resistance to thyroid hormone; TSH secreting adenoma; thyreotropin

Received: August 30, 2016; Accepted: September 13, 2016; Published: June 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ježková J, Marek J. TSH secreting adenomas. Vnitr Lek. 2016;62(Supplementum 3):77-81.
Download citation

References

  1. Davis JRE, Farrel WE, Clayton RN. Pituitary tumors. Reproduction 2001; 121(3): 363-371. Go to original source... Go to PubMed...
  2. Raappana A, Koivukangas J, Ebeling T et al. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010; 95(9): 4268-4275. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2010-0537>. Go to original source... Go to PubMed...
  3. Önnestam L, Berinder K, Burman P et al. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J Clin Endocrinol Metab 2013; 98(2): 626-635. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2012-3362>. Go to original source... Go to PubMed...
  4. Saeger W, Lüdecke DK, Buchfelder M et al. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Register. Eur J Endocrinol 2007; 156(2): 203-216. Go to original source... Go to PubMed...
  5. Jailer JW, Holub DA. Remission of Graves' disease following radiotherapy of a pituitary neoplasm. Am J Med 1960; 28: 497-500. Go to original source... Go to PubMed...
  6. Kovacs K, Horvath E. Tumors of the pituitary gland. In: Harthmann WH, Sobin LH. Atlas of Tumor Pathology, fascicle 21, series 2. Armed Forced Institute of Pathology: Washington, DC 1986.
  7. Thotakura NR, LiCalzi L, Weintraub BD. The role of carbohydrate in thyrotropin action assessed by a novel method of enzymatic deglycosylation. J Biol Chem 1990; 265(20): 11527-11534. Go to original source... Go to PubMed...
  8. Friedmann JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395(6704): 763-770. Go to original source... Go to PubMed...
  9. Urman S, Critchlow V. Long-term elevations in plasma thyrotropin, but not growth hormone, concentrations associated with lesion-induced depletion of median eminence somatostatin. Endocrinology 1983; 112(2): 659-664. Go to original source... Go to PubMed...
  10. Foord SM, Peters JR, Dieguez C et al. Dopamine receptors on intact anterior pituitary cells in culture: Functional association with the inhibition of prolactin and thyrotropin. Endocrinology 1983; 112(5): 1567-1577. Go to original source... Go to PubMed...
  11. Fekete C, Kelly J, Mihaly E et al. Neuropeptide Y has a central inhibitory action on the hypothalamic-pituitary-thyroid axis. Endocrinology 2001; 142(6): 2606-2613. Go to original source... Go to PubMed...
  12. Roelsfema F, Pereira AM, Biermasz NR et al. Diminished and irregular TSH secretion with delayed acrophase in patients with Cushing's syndrome. Eur J Endocrinol 2009; 161(5): 695-703. Dostupné z DOI: <http://dx.doi.org/10.1530/EJE-09-0580>. Go to original source... Go to PubMed...
  13. Hermus RM, Sweep CG, van der Meer MJ et al. Continuous infusion of interleukin-1 induces a non-thyroidal illness syndrome in the rat. Endocrinology 1992; 131(5): 2139-2146. Go to original source... Go to PubMed...
  14. Van der Poll T, Romijn JA, Wiersinga WM et al. Tumor necrosis factor: A putative mediator of the sick euthyroid syndrome in man. J Clin Endocrinol Metab 1990; 71(6): 1567-1572. Go to original source... Go to PubMed...
  15. Torpy DJ, Tsigos C, Lotsikas AJ et al. Acute and delayed effects of a single-dose injection of interleukin-6 on thyroid function in healthy humus. Metabolism 1998; 47(10): 1289-1293. Go to original source... Go to PubMed...
  16. Banerjee AK, Sharma BS, Kak VK. Clinically and biochemically silent thyrotroph adenoma with oncocytic change. Neurol India 2000; 48(4): 374-377. Go to PubMed...
  17. Ma W, Ikeda H, Watabe N et al. A plurihomonal TSH-producing pituitary tumor of monoclonal origin in a patient with hypothyroidism. Horm Res 2003; 59(5): 257-261. Go to original source... Go to PubMed...
  18. Taylor TJ, Donlon SS, Bale AE et al. Treatment of a thyrotropinoma with octreotide - LAR in patient with multiple endocrine neoplasia 1. Thyroid 2000; 10(11): 1001-1007. Go to original source... Go to PubMed...
  19. Gessl A, Freissmuth M, Czech T et al. Growth hormone-prolactin-thyrotropin-secreting pituitary adenoma in atypical McCune-Albright syndrome with functionally normal Gs alpha protein. J Clin Endocrinol Metab 1994; 79(4): 1128-1134. Go to original source...
  20. Tichomirowa MA, Daly AF, Beckers A. Familiar pituitary adenomas. J Intern Med 2009; 266(1): 5-18. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2796.2009.02109.x>. Go to original source... Go to PubMed...
  21. Ezzat S, Horvath E, Kovacs K et al. Basic fibroblast growth factor expression in two prolactin and thyrotropin-producing pituitary adenomas. Endocr Pathol 1995; 6(2): 125-134. Go to original source... Go to PubMed...
  22. Mixson AJ, Friedman TC, Katz DA et al. Thyrotropin-secreting pituitary carcinoma. J Clin Endocrinol Metab 1993; 76(2): 529-533. Go to original source...
  23. Brown RL, Muzzafar T, Wollman R et al. A pituitary carcinoma secreting TSH and prolactin: A non-secreting adenom agone awry. Eur J Endocrinol 2006; 154(5): 639-643. Go to original source... Go to PubMed...
  24. Lee W, Cheung AS, Freilich R. TSH-secreting pituitary carcinoma with intrathecal drop metastase. Clin Endocrinol 2012; 76(4): 604-606. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2265.2011.04288.x>. Go to original source... Go to PubMed...
  25. Socin HV, Chanson P, Delemer B et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003; 148(4): 433-442. Go to original source... Go to PubMed...
  26. George JT, Thow JC, Matthews B et al. Atrial fibrillation associated with a thyroid stimulating hormone-secreting adenoma of the pituitary gland leading to a presentation of acute cardiac decompensation: a case report. J Med Case Rep 2008; 28: 67. Dostupné z DOI: <http://dx.doi.org/10.1186/1752-1947-2-67>. Go to original source... Go to PubMed...
  27. Yovos JG, Falko JM, O'Dorisio TM et al. Thyrotoxicosis and a thyrotroping-sereting pituitary tumor causing unilateral exophtalmos. J Clin Endocrinol Metab 1981; 53(2): 338-343. Go to original source... Go to PubMed...
  28. Poggi M, Monti S, Pascucci C et al. A rare case of follicular thyroid carcinoma in a patient with thyrotropin-secreting pituitary adenoma. Am J Med Sci 2009; 337(6): 462-465. Dostupné z DOI: <http://dx.doi.org/10.1097/MAJ.0b013e3181949948>. Go to original source... Go to PubMed...
  29. Perticone F, Pigliaru F, Marriotti S et al. Is the incidence of differentiated thyroid cancer increased in patients with thyrotropin-secreting adenomas? Thyroid 2015; 25(4): 417-424. Dostupné z DOI: <http://dx.doi.org/10.1089/thy.2014.0222>. Go to original source... Go to PubMed...
  30. Kuhn JM, Arlot S, Lefebvre H et al. Evaluation of the treatment of thyroid-secreting pituitary adenomas with a slow release of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000; 85(4): 1487-1491. Go to original source... Go to PubMed...
  31. Beck-Peccoz P, Persani L. Variable biological activity of thyroid-stmulating hormone. Eur J Endocrinol 1994; 131(4): 331-340. Go to original source... Go to PubMed...
  32. Magner JA, Klibanski A, Fein H et al. Ricin and lentil lectin affinity chromatografy reveals oligosaccharide heterogenity of thyrotropin secreted by 12 human pituitary tumors. Metabolism 1992; 41(9): 1009-1015. Go to original source... Go to PubMed...
  33. Losa M, Giovanelli M, Persani L et al. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996; 81(8): 3084-3090. Go to original source...
  34. Brucker-Davis F, Oldfield EH, Skarulis MC et al. Thyrotropin-secreting pituitary tumors: Diagnosis criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab1999; 84(2): 476-486. Go to original source... Go to PubMed...
  35. Beck-Peccoz P, Roncoroni R, Mariotti S et al. Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. J Clin Endocrinol Metab 1990; 71(1): 19-25. Go to original source... Go to PubMed...
  36. Beck-Peccoz P, Persani L. TSH-producing adenomas. In: Jameson JL, DeGroot LJ (eds). Endocrinology. 5th ed. Saunders USA: 2006: 324-332. ISBN 9780721603766. Go to original source...
  37. Beck-Peccoz P, Persani L, Mannavola D et al. Pituitary tumours: TSH-secretin adenomas. Best Pract Res Clin Endocrinol Metab 2009; 23(5): 597-606. Dostupné z DOI: <http://dx.doi.org/10.1016/j.beem.2009.05.006>. Go to original source... Go to PubMed...
  38. Clarke MJ, Erickson D, Castro MR et al. Thyroid-stimulating hormone pituitary adenomas. J Neurosurg 2008; 109(1): 17-22. Dostupné z DOI: <http://dx.doi.org/10.3171/JNS/2008/109/7/0017>. Go to original source... Go to PubMed...
  39. Cooper DS, Wening BM. Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumor. Thyroid 1996; 6(4): 337-343. Go to original source... Go to PubMed...
  40. Glendenning P, Siriwardhana D, Hoad K et al. Thyroxine autoantibody interference is an uncommon cause of inappropriate TSH secretion using the Immulite 2000 assay. Clin Chim Acta 2009; 403(1-2): 136-138. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cca.2009.02.002>. Go to original source... Go to PubMed...
  41. Tan MJ, Tan F, Hawkins R et al. A hyperthyroid patient with measurable thyroid-stimulating hormone concentration - a trap for the unwary. Ann Acad Med Singapore 2006; 35(7): 500-503. Go to original source...
  42. Cartwright D, O'Shea P, Rajanayagam O et al. Familiar dysalbuminemic hyperthyroxinemia: A persistent diagnostic challenge. Clin Chem 2009; 55(5): 1044-1046. Dostupné z DOI: <http://dx.doi.org/10.1373/clinchem.2008.120303>. Go to original source... Go to PubMed...
  43. Slezak R, Lukienczuk T, Noczynska A et al. A novel p.E311K mutation of thyroid receptor beta gene in resistence to thyroid hormone syndrome, inherited in autosomal recessive trait. Horm Metab Res 2012; 44(9): 704-707. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0032-1312666>. Go to original source... Go to PubMed...
  44. Dumitrescu AM, Refetoff S. The syndromes of reduced sensitivity to thyroid hormone. Biochim Biophys Acta 2013; 1830(7): 3987-4003. Dostupné z DOI: <http://dx.doi.org/10.1016/j.bbagen.2012.08.005>. Go to original source... Go to PubMed...
  45. Weiss WR, Refetoff S. Resistance to Thyroid Hormone (RTH) (non TR-RTH). Hot Thyroidol 2009; 9: 1-11.
  46. Gurnell M, Halsall DJ, Chatterjee VK. What should be done when thyroid function tests do not make sense? Clin Endocrinol 2011; 74(6): 673-678. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2265.2011.04023.x>. Go to original source... Go to PubMed...
  47. Beck-Peccoz P, Brucker-Davis F, Persani L et al. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996; 17(6): 610-638. Go to original source...
  48. Yamada S, Fukuhara N, Horiguchi K et al. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases. J Neurosurg 2014; 121(6): 1462-1473. Dostupné z DOI: <http://dx.doi.org/10.3171/2014.7.JNS1471>. Go to original source... Go to PubMed...
  49. Kirkman MA, Jaunmutkane Z, Brandner S et al. Active and silent thyroid-stimulating hormone-expressing pituitary adenomas: presenting symptoms, treatment, outcomes, and recurrence. World Neurosurg 2014; 82(6): 1224-1231. Dostupné z DOI: <http://dx.doi.org/10.1016/j.wneu.2014.03.031>. Go to original source... Go to PubMed...
  50. Caron P, Arlot S, Bauters C et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 2001; 86(6): 2849-2853. Go to original source... Go to PubMed...
  51. Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 2002; 5(2): 83-88. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.